A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Part of paid clinical trials in Los Alamitos, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07152002
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy
  • Overweight or Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4064912 — DRUG
    Administered SC
  • LY4064912 — DRUG
    Administered IV
  • Placebo — DRUG
    Administered SC
  • Placebo — DRUG
    Administered IV

Study Details

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Key Dates

First listed
Sep 3, 2025
Start date
Aug 28, 2025
Status verified
Aug 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part A: LY4064912 (Cohorts 1-6)
    LY4064912 administered subcutaneously (SC)
  • Experimental: Part A: LY4064912 (Cohort 6a)
    LY4064912 administered intravenously (IV)
  • Placebo Comparator: Part A: Placebo
    Placebo administered SC and IV
  • Experimental: Part B: LY4064912 (Cohorts 7-10)
    LY4064912 administered SC
  • Placebo Comparator: Part B: Placebo
    Placebo administered SC
  • Experimental: Part C: LY4064912 (Cohort 11)
    LY4064912 administered SC
  • Experimental: Part C: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Postdose to Approximately Week 27 ]

Locations (2)

FacilityCityStateZIPSite coordinators
Collaborative Neuroscience Network - CNSLos AlamitosCalifornia90720-
ICON Early Phase ServicesSan AntonioTexas78209-

Find similar trials in Los Alamitos, CA

By research site
Collaborative Neuroscience Network - CNS· Los Alamitos, CAICON Early Phase Services· San Antonio, TX

Related Studies